Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer Journal Article

  


Authors: Fennelly, D.; Aghajanian, C.; Shapiro, F.; O'Flaherty, C.; McKenzie, M.; O'Connor, C.; Tong, W.; Norton, L.; Spriggs, D.
Article Title: Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer
Abstract: Purpose: Paclitaxel has shown significant activity in advanced ovarian cancer. In vitro studies with paclitaxel have suggested that fractionated brief infusion schedules may be more effective than the standard 24-hour infusion. We commenced a phase I evaluation of escalating-dose paclitaxel (40, 50, 60, 80, 100 mg/m2) administered weekly as a 1-hour infusion in patients with recurrent ovarian cancer. All patients had received prior paclitaxel and cisplatin therapy. All patients received standard premeditation. Patients and Methods: Eighteen patients are assessable on this phase I study. The mean age was 54 years (range, 48 to 74). The median number of prior chemotherapy regimens was three (range, two to five). The mean paclitaxel-free interval was 10.1 months (range, 1 to 24). Results: A total of 194 cycles of therapy were administered, with a mean of 10 (range, one to 12) per patient. No mucositis or grade III neuropathy was seen. Alopecia occurred in one out of 18 assessable patients. The mean neutrophil nadir was 4.0 x 109/L. At the top dose level (100 mg/m2) delivered, dose-intensity was 90.75% of that planned and greater than two fold the standard dose- intensity. Partial responses were seen in four of 13 assessable patients (30%). Two patients with progression of disease on standard three-week paclitaxel schedules switched to a weekly schedule with demonstrated response. Increasing paclitaxel dose correlated with measured area under the curve (AUC) (R2 = .614). Dose-limiting toxicity was reached at 100 mg/m2 with two of three patients experiencing a treatment delay, thus defining a maximum-tolerated dose of 80 mg/m2 in this group of heavily pretreated patients on this weekly schedule. Conclusion: (1) Paclitaxel administered as a 1-hour infusion is well tolerated; (2) this schedule of administration does not result in cumulative myelosuppression; and (3) this schedule of administration results in dose-intensive paclitaxel delivery with a favorable toxicity profile.
Keywords: adult; cancer chemotherapy; clinical article; aged; middle aged; clinical trial; neutropenia; treatment planning; paclitaxel; recurrent cancer; ovarian neoplasms; ovary cancer; neoplasm recurrence, local; drug administration schedule; antineoplastic agents, phytogenic; antineoplastic activity; phase 1 clinical trial; adenocarcinoma, clear cell; carcinoma, endometrioid; cystadenocarcinoma, mucinous; cystadenocarcinoma, papillary; humans; human; female; priority journal; article
Journal Title: Journal of Clinical Oncology
Volume: 15
Issue: 1
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 1997-01-01
Start Page: 187
End Page: 192
Language: English
PUBMED: 8996141
PROVIDER: scopus
DOI: 10.1200/JCO.1997.15.1.187
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031036177&partnerID=40&md5=4f6051803c0b9622162e07a63f258069
Notes: Article -- Export Date: 17 March 2017 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. William Ping-Yiu Tong
    158 Tong
  2. Larry Norton
    758 Norton
  3. Carol A Aghajanian
    607 Aghajanian
  4. David R Spriggs
    325 Spriggs
  5. Catherine A O'Flaherty
    12 O'Flaherty
  6. Fred Shapiro
    37 Shapiro
  7. David Fennelly
    51 Fennelly
Related MSK Work